[go: up one dir, main page]

WO2008144365A3 - Procédé de fabrication de compositions de poudre sèche contenant des acides nucléiques - Google Patents

Procédé de fabrication de compositions de poudre sèche contenant des acides nucléiques Download PDF

Info

Publication number
WO2008144365A3
WO2008144365A3 PCT/US2008/063655 US2008063655W WO2008144365A3 WO 2008144365 A3 WO2008144365 A3 WO 2008144365A3 US 2008063655 W US2008063655 W US 2008063655W WO 2008144365 A3 WO2008144365 A3 WO 2008144365A3
Authority
WO
WIPO (PCT)
Prior art keywords
supercritical fluid
powder compositions
dry powder
compositions containing
fluid technology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/063655
Other languages
English (en)
Other versions
WO2008144365A2 (fr
Inventor
Andrew Geall
Sushma Kommareddy
Gerhard Muhrer
Vishal Saxena
Ranjit Thakur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2008144365A2 publication Critical patent/WO2008144365A2/fr
Publication of WO2008144365A3 publication Critical patent/WO2008144365A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé de fabrication de compositions de poudre sèche comportant des molécules double brin d'acide nucléique. Le procédé selon l'invention peut être utilisé pour former des particules à partir d'un fluide supercritique basé sur un traitement à base d'anti-solvant pouvant être utilisées ultérieurement pour administration pharmaceutique, notamment pour une administration parentérale.
PCT/US2008/063655 2007-05-17 2008-05-15 Procédé de fabrication de compositions de poudre sèche contenant des acides nucléiques Ceased WO2008144365A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93850407P 2007-05-17 2007-05-17
US60/938,504 2007-05-17

Publications (2)

Publication Number Publication Date
WO2008144365A2 WO2008144365A2 (fr) 2008-11-27
WO2008144365A3 true WO2008144365A3 (fr) 2009-02-19

Family

ID=39651059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063655 Ceased WO2008144365A2 (fr) 2007-05-17 2008-05-15 Procédé de fabrication de compositions de poudre sèche contenant des acides nucléiques

Country Status (1)

Country Link
WO (1) WO2008144365A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) * 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
WO2004066806A2 (fr) * 2003-01-24 2004-08-12 The Regents Of The University Of California Dispositif aerosol pour distribuer un agent bioactif
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
WO2005089718A2 (fr) * 2004-03-23 2005-09-29 Novartis Ag Compositions pharmaceutiques
WO2006105361A2 (fr) * 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibiteurs de la sous-unite 2 de la ribonucleotide reductase et utilisations associees
WO2007072106A1 (fr) * 2005-12-22 2007-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede pour la preparation de particules a partir d'une emulsion dans co2 supercritique ou liquide
WO2007080127A2 (fr) * 2006-01-12 2007-07-19 Devgen N.V. Procedes destines a lutter contre des parasites au moyen d'arni
WO2008021451A2 (fr) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Inhalateur à poudre sèche actionné par l'homme et compositions à inhaler sous forme de poudre sèche

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US6630121B1 (en) * 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
WO2004066806A2 (fr) * 2003-01-24 2004-08-12 The Regents Of The University Of California Dispositif aerosol pour distribuer un agent bioactif
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
WO2005089718A2 (fr) * 2004-03-23 2005-09-29 Novartis Ag Compositions pharmaceutiques
WO2006105361A2 (fr) * 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibiteurs de la sous-unite 2 de la ribonucleotide reductase et utilisations associees
WO2007072106A1 (fr) * 2005-12-22 2007-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede pour la preparation de particules a partir d'une emulsion dans co2 supercritique ou liquide
WO2007080127A2 (fr) * 2006-01-12 2007-07-19 Devgen N.V. Procedes destines a lutter contre des parasites au moyen d'arni
WO2008021451A2 (fr) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Inhalateur à poudre sèche actionné par l'homme et compositions à inhaler sous forme de poudre sèche

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOVANOVIC N ET AL: "Stabilization of proteins in dry powder formulations using supercritical fluid technology", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 11, 1 November 2004 (2004-11-01), pages 1955 - 1969, XP002404648, ISSN: 0724-8741 *
JUNG J ET AL: "Particle design using supercritical fluids: Literature and patent survey", JOURNAL OF SUPERCRITICAL FLUIDS, PRA PRESS, US, vol. 20, no. 3, 1 August 2001 (2001-08-01), pages 179 - 219, XP004735157, ISSN: 0896-8446 *
OKAMOTO H ET AL: "Stability of chitosan-pDNA complex powder prepared by supercritical carbon dioxide process", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 290, no. 1-2, 16 February 2005 (2005-02-16), pages 73 - 81, XP004967392, ISSN: 0378-5173 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US8754062B2 (en) 2011-12-16 2014-06-17 Moderna Therapeutics, Inc. DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
WO2008144365A2 (fr) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008144365A3 (fr) Procédé de fabrication de compositions de poudre sèche contenant des acides nucléiques
WO2008138755A3 (fr) Compositions pharmaceutiques pour des médicaments solubles de façon médiocre
WO2008122965A3 (fr) Compositions pharmaceutiques à base de cyclosporine
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2010031720A3 (fr) Nouvelle formulation d’anticorps
WO2010058941A3 (fr) Procédé de production de nanofils métalliques au moyen de liquides ioniques
WO2008073942A3 (fr) Compositions pharmaceutiques et leurs procédés d'utilisation
WO2011131947A3 (fr) Procédé de traitement de particules de principes actifs pharmaceutiques
WO2010006173A3 (fr) Complexe minéral-acide aminé-polysaccharide
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
IL216522A (en) Durable dosage form, packing containing it and method of preparation
WO2009023434A3 (fr) Procédé de stabilisation de la phényléphrine
EP2216015A4 (fr) Produit complexe de substance médiocrement soluble-agent tensio-actif, et son procédé de fabrication
WO2008139902A1 (fr) Fines particules de gel sensibles aux molécules, leur méthode de production et d'utilisation
EP2351764A4 (fr) Composé de tréhalose, son procédé de fabrication et produit pharmaceutique contenant le composé
WO2006122317A3 (fr) Procedes et dispositifs de nanofabrication pour l'assemblage controle de nanostructures fonctionnalisees
WO2008049633A8 (fr) Séchage par percolation pour la préparation de particules
WO2008065282A3 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
WO2009007992A8 (fr) Compositions pharmaceutiques
WO2012108631A3 (fr) Compositions pharmaceutiques comprenant des nanoparticules qui contiennent du révaprazan et procédés de préparation associés
WO2009015791A3 (fr) Produits de confiserie améliorés et leur procédé de fabrication
WO2011067236A3 (fr) Polymorphes de raltegravir
ZA200904530B (en) Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same
WO2008125239A3 (fr) Extraits secs constitués de pelargonium sidoïdes et de pélargonium réniforme
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08769472

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08769472

Country of ref document: EP

Kind code of ref document: A2